Treatment of GHB withdrawal syndrome: Catch 22 or challenge for addiction medicine? by Jong, C.A.J. de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/121979
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Letters to the Editor
The journal publishes both invited and unsolicited letters.
TREATMENT OF GHB WITHDRAWAL
SYNDROME: CATCH 22 OR CHALLENGE
FOR ADDICTION MEDICINE?
The literature provides little information on the process of
detoxification from gamma-hydroxybutyric acid (GHB).
We have studied this topic and developed three guidelines
that we thought might be of interest to your readers.
These guidelines can be found at http://www.nispa.nl.
We also wish to issue a call for action and sharing
experiences in case of problems caused by the use of
‘less well known’ psychoactive substances.
GHB is an endogenous neurotransmitter and a
popular drug of abuse. The lifetime prevalence in 2009 in
the Netherlands was 1.3% and in the last year 0.4%
among the general population [1]. From 2007 to 2011
an increase from80 to 659 patients seeking treatment for
GHB dependence was reported. In cases of dependence
serious symptoms of acute GHB withdrawal can develop.
Complications can be life-threatening and require inten-
sive supportive care in a medical setting. The rapid
increase in the number of GHB users combined with
complicated withdrawal point to the need for expert
medical knowledge. However, knowledge is only available
from case reports that suggest the use of high doses of
benzodiazepines, short-acting barbiturates or propofol,
and sometimes general anesthesia in an intensive care
unit setting, with limited effect.
Catch-22
There are no studies or guidelines on safe and effective
detoxification methods for GHB dependence. This results
in a catch-22 situation: without well-tested effective
interventions there can be no guidelines, but without
guidelines there can be no consensus about interven-
tions. This leaves addiction medicine empty-handed. This
is not unique to GHB-related problems, as addiction
medicine is frequently confronted with new or changing
trends in use of drugs, and randomised clinical trials
are difficult to set up.
We regarded this situation as a challenge to provide a
quick and well performed action-oriented study produc-
ing well evaluated and widely supported practice-based
recommendations.
Our institute evaluated the titration and tapering
method [2] with pharmaceutical GHB in six Dutch
addiction treatment facilities from 2010 to 2012,
as a clinical cohort study, and organised consensus
meetings. We included 274 GHB-dependent patients;
90% detoxified without complications. The GHB-Monitor
project resulted in three practice-based recommendations
for detoxification: in an inpatient addiction treatment
setting, in a general hospital and in an outpatient
setting.
The project shows that innovative collaboration
among addiction specialists (a less complicated option
than a multi-centre study) transformed the initial
catch-22 situation in a successful project., We also want
to share our knowledge and expertise internationally.
Based on a coincidental network with the Swiss
Association of Addiction Medicine our Dutch recom-
mendations will be translated into French, Italian and
German. We regard these results as highly successful
and want to encourage similar collaborations, allowing
addiction medicine to mature. The European Federa-
tion of Addiction Societies could be an influential
platform from which to promote such international
collaboration.
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